Human urotensin-II exhibits potent contractile activity in primate airway and pulmonary vascular tissues, suggesting a potential pathophysiological role in lung diseases.
Answers are grounded in this paper and cite their sources.
Suggests urotensin-II may contribute to pulmonary tone; leaves open its role in human lung disease.
The contractile profile of human urotensin-II (hU-II) was examined in primate airway and pulmonary vascular tissues. hU-II contracted tissues from different airway regions with similar potencies (pD(2)s from 8.6 to 9.2). However, there were regional differences in the efficacy of hU-II, with a progressive increase in the maximum contraction from trachea to smaller airway regions (from 9 to 41% of the contraction to 10 microM carbachol). hU-II potently contracted pulmonary artery tissues from different regions with similar potencies and efficacies: pD(2)s=8.7 to 9.3 and maximal contractions=79 to 86% of 60 mM KCl. hU-II potently contracted pulmonary vein preparations taken proximal to the atria, but had no effect in tissues from distal to the atria. This is the first report describing the contractile activity of hU-II in airways and suggests that the potential pathophysiological role of this peptide in lung diseases warrants investigation.
No takes yet. Share an insight, caveat, or question.
Hay et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: